In 2022,Khiar-Fernandez, Nora; Zian, Debora; Vazquez-Villa, Henar; Martinez, R. Fernando; Escobar-Pena, Andrea; Foronda-Sainz, Roman; Ray, Manisha; Puigdomenech-Poch, Maria; Cincilla, Giovanni; Sanchez-Martinez, Melchor; Kihara, Yasuyuki; Chun, Jerold; Lopez-Vales, Ruben; Lopez-Rodriguez, Maria L.; Ortega-Gutierrez, Silvia published an article in Journal of Medicinal Chemistry. The title of the article was 《Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA2), UCM-14216, Ameliorates Spinal Cord Injury in Mice》.Product Details of 683-57-8 The author mentioned the following in the article:
Spinal cord injuries (SCIs) irreversibly disrupt spinal connectivity, leading to permanent neurol. disabilities. Current medical treatments for reducing the secondary damage that follows the initial injury are limited to surgical decompression and anti-inflammatory drugs, so there is a pressing need for new therapeutic strategies. Inhibition of the type 2 lysophosphatidic acid receptor (LPA2) has recently emerged as a new potential pharmacol. approach to decrease SCI-associated damage. Toward validating this receptor as a target in SCI, we have developed a new series of LPA2 antagonists, among which compound 54 (UCM-14216) stands out as a potent and selective LPA2 receptor antagonist (Emax = 90%, IC50 = 1.9 μM, KD = 1.3 nM; inactive at LPA1,3-6 receptors). This compound shows efficacy in an in vivo mouse model of SCI in an LPA2-dependent manner, confirming the potential of LPA2 inhibition for providing a new alternative for treating SCI.2-Bromoacetamide(cas: 683-57-8Product Details of 683-57-8) was used in this study.
2-Bromoacetamide(cas: 683-57-8) can be used in preparation of (2-carbamoylmethoxy-5-chloro-benzyl)-carbamic acid tert-butyl ester. It was aslo used as precursor to dehydropeptidase I inactivator.Product Details of 683-57-8
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics